46 results
8-K
EX-10.4
ADAP
Adaptimmune Therapeutics Plc
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
of the Company receiving the offer, the Company shall refer the dispute to a mutually acceptable independent expert (or, if agreement is not reached … within five Business Days of either party giving notice to the other that it wishes to refer a matter to an independent expert, such independent expert
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Jul 18
Departure of Directors or Certain Officers
5:00pm
on such terms within 30 days of the Company receiving the offer, the Company shall refer the dispute to a mutually acceptable independent expert … expert, such independent expert as may be nominated by an appropriate authority, which the parties shall seek in good faith to agree) (the “Expert
8-K
EX-10.2
ADAP
Adaptimmune Therapeutics Plc
13 Aug 21
Entry into a Material Definitive Agreement
4:33pm
Principal Rent following each Review Date pursuant to paragraph 2 of the Second Schedule.
Expert means a surveyor (who shall be a Fellow of the Royal … Date shall be:
agreed in writing between the Landlord and the Tenant; or
determined by an Expert (acting as an expert) on the application of either
10-K
2016 FY
EX-10.17
ADAP
Adaptimmune Therapeutics Plc
13 Mar 17
Annual report
12:00am
of the Company receiving the offer, the Company shall refer the dispute to a mutually acceptable independent expert (or, if agreement is not reached within … five Business Days of either party giving notice to the other that it wishes to refer a matter to an independent expert, such independent expert as may
8-K
EX-10.2
61p d2ujurrrj
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
8z37 96rv09d
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.3
k8z2d98dld5
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
jg7yfy146unmql8z no8
27 Jun 19
Departure of Directors or Certain Officers
8:08am
8-K
EX-10.1
l4sdt5dz jdrs
18 Feb 20
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
8:07am
DRS
EX-10.10
pco51 b18j2fs8twzzfk
5 Feb 15
Draft registration statement
12:00am
8-K
EX-10.1
gi3entv67
13 Aug 21
Entry into a Material Definitive Agreement
4:33pm
S-4/A
EX-99.2
s1km905vugr6ikgs0ic
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
5uc ot1ly5p9
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
S-4
EX-99.1
24c9s8bzt6 wke7ast
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
S-4
EX-99.2
8qmh4
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm